Antibody-Drug Conjugate Active in Resistant NSCLC

(MedPage Today) -- An antibody-drug conjugate targeting the HER3 growth factor receptor had significant clinical activity in EGFR inhibitor-resistant non-small cell lung cancer (NSCLC), according to results from a study reported at the 2021 virtual...